IL-17 inhibitors fundamentally changed what doctors and patients expect from psoriasis treatment. Before secukinumab received FDA approval in January 2015, the gold standard was a 75 percent reduction in the Psoriasis Area and Severity Index — known as PASI 75 — and most patients accepted that living with some visible disease was simply part of the deal. IL-17 inhibitors shattered that ceiling. Today, complete skin clearance — PASI 100 — is a realistic goal for the majority of patients, with newer agents like bimekizumab pushing complete clearance rates above 60 percent at just 16 weeks of treatment.
That shift, from managing symptoms to eliminating them, represents one of the most significant paradigm changes in modern dermatology. This matters for the roughly 125 million people worldwide living with psoriasis, a population that represents 2 to 3 percent of the global population according to the National Psoriasis Foundation. In the United States alone, approximately 3 percent of adults have psoriasis, and an estimated 600,000 are living with undiagnosed disease. With global incidence projected to rise through 2050, the availability of treatments that can deliver rapid, near-total clearance has enormous implications for quality of life, mental health, and the systemic inflammation increasingly linked to cognitive decline and other comorbidities. This article examines how the four FDA-approved IL-17 inhibitors work, what the clinical data actually shows, who they help most, and where their limitations lie.
Table of Contents
- How Did IL-17 Inhibitors Change Psoriasis Treatment Standards?
- The Four FDA-Approved IL-17 Inhibitors and How They Differ
- What the Clinical Trial Data Shows About Skin Clearance
- Safety Profile — Candidiasis, IBD Risk, and What to Watch For
- Speed of Response and Why It Matters for Quality of Life
- The Psoriasis-Brain Health Connection
- What Comes Next — The BE BOLD Trial and Beyond
- Conclusion
- Frequently Asked Questions
How Did IL-17 Inhibitors Change Psoriasis Treatment Standards?
Before 2015, the biologic treatment landscape for moderate-to-severe psoriasis was dominated by TNF inhibitors — drugs like adalimumab, etanercept, and infliximab — along with conventional systemic therapies such as methotrexate and phototherapy. These treatments helped many patients, but they were slow to act, often requiring 12 or more weeks to reach peak efficacy, and the bar for success was modest. A PASI 75 response, meaning a 75 percent improvement in skin disease, was considered a strong outcome. Complete clearance was rare enough that most clinical trials did not even report it as a primary endpoint. IL-17 inhibitors changed the conversation in three concrete ways. First, they delivered dramatically higher rates of complete or near-complete clearance. Second, they worked faster, with PASI 90 responses appearing at approximately 6 to 8 weeks — roughly half the time required by older biologics.
Third, they forced the field to raise its expectations. When a drug class routinely clears skin entirely, it becomes difficult to justify settling for partial improvement. The 2019 Joint AAD-NPF Guidelines reflected this shift by recommending secukinumab as a first-line biologic agent for adults with moderate-to-severe psoriasis, with or without psoriatic arthritis. Head-to-head trials showing IL-17 inhibitors’ superior efficacy over TNF inhibitors further cemented their position at the top of the treatment hierarchy. The practical consequence for patients has been profound. A person who previously cycled through methotrexate, phototherapy, and a TNF inhibitor over the course of years — achieving partial improvement at each step — can now reasonably expect clear skin within two months of starting an IL-17 inhibitor. That is not a marketing claim. It is what the phase 3 trial data consistently demonstrates.
The Four FDA-Approved IL-17 Inhibitors and How They Differ
Four IL-17 inhibitors have received FDA approval for plaque psoriasis, and while they share a mechanism of action, they are not interchangeable. Secukinumab, marketed as Cosentyx, was the first to arrive in January 2015. Manufactured by Novartis, it targets IL-17A and established the proof of concept that blocking this specific cytokine could produce superior outcomes compared to existing biologics. Ixekizumab, sold as Taltz, followed in March 2016 from Eli Lilly. It also targets IL-17A but binds with higher affinity than secukinumab, which may partly explain its slightly higher clearance rates in some comparisons. Brodalumab, branded as Siliq and manufactured by Bausch Health, took a different approach when it was approved in February 2017.
Rather than neutralizing the IL-17 cytokine itself, brodalumab targets the IL-17 receptor A, effectively blocking multiple IL-17 isoforms including IL-17A and IL-17F. This broader blockade was an early hint that inhibiting more than one IL-17 family member might matter. That idea reached its fullest expression with bimekizumab, marketed as Bimzelx by UCB, which received FDA approval on October 17, 2023. Bimekizumab is the first dual IL-17A and IL-17F inhibitor, and in September 2024 it received expanded approvals for psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. However, the differences between these drugs are not always clinically decisive for every patient. A person who responds well to secukinumab and tolerates it without issue has little reason to switch solely because a newer agent exists. The choice between IL-17 inhibitors often comes down to dosing convenience, insurance coverage, individual side effect profiles, and whether the patient has comorbid conditions like inflammatory bowel disease that might steer the decision in a different direction.
What the Clinical Trial Data Shows About Skin Clearance
The efficacy numbers from IL-17 inhibitor trials are striking even by the standards of modern biologic therapy. In the BE RADIANT trial, published in the new England Journal of Medicine, bimekizumab was compared head-to-head against secukinumab. At week 16, 61.7 percent of bimekizumab patients achieved complete skin clearance — a PASI 100 response — compared with 48.9 percent for secukinumab. By week 48, the gap widened further: 67.0 percent versus 46.2 percent. These are not marginal differences. For a patient choosing between the two, bimekizumab offered roughly a 20-percentage-point advantage in complete clearance at one year. Long-term data reinforces this durability.
Four-year follow-up data for bimekizumab showed that 64.7 percent of patients maintained complete skin clearance through 196 weeks, with 86.1 percent achieving PASI 90. For secukinumab, five-year durability data showed PASI 75, 90, and 100 rates of 88.9 percent, 68.5 percent, and 43.8 percent at year one, maintaining at 88.5 percent, 66.4 percent, and 41 percent through year five. A network meta-analysis looking at short-term results across the class found PASI 90 rates of 72.9 percent for ixekizumab, 72.0 percent for brodalumab, and 65.0 percent for secukinumab at 10 to 16 weeks. For PASI 100, ixekizumab achieved 41.4 percent and brodalumab 40.3 percent in the same timeframe. One important caveat: clinical trial populations are carefully selected, and real-world response rates are typically somewhat lower. Patients with significant comorbidities, obesity, or prior biologic failure may not reach the clearance rates reported in pivotal trials. Still, even with that discount, the IL-17 class delivers outcomes that were essentially unimaginable in the pre-biologic era.
Safety Profile — Candidiasis, IBD Risk, and What to Watch For
No discussion of IL-17 inhibitors is complete without a frank look at their safety trade-offs. The most notable class-specific adverse effect is candidiasis — yeast infections, particularly oral and genital — which makes biological sense because IL-17 plays a key role in the body’s defense against fungal pathogens. Pooled clinical trial data shows candidiasis rates of 2.2 per 100 patient-years in psoriasis, 1.5 in psoriatic arthritis, and 0.7 in ankylosing spondylitis. Critically, all reported cases were mild to moderate, and no systemic candidiasis was observed. Most cases resolve with standard antifungal treatment and do not require discontinuation of the biologic. The more concerning question involves inflammatory bowel disease.
Cases of new-onset or exacerbated Crohn’s disease and ulcerative colitis have been reported in patients receiving IL-17 inhibitors, and the drugs are contraindicated in patients with active IBD. This is an area where prescribers must exercise genuine caution, particularly in patients with gastrointestinal symptoms or a family history of IBD. However, recent analyses of 21 clinical trials found that the IBD incidence rates among IL-17 inhibitor users were comparable to those observed in untreated psoriasis patients, suggesting the relationship may be more nuanced than early warnings implied. Overall, the safety profile of IL-17 inhibitors is comparable to other approved biologics and is generally considered favorable relative to older systemic agents like methotrexate, which carries risks of hepatotoxicity and bone marrow suppression. For most patients, the benefit-risk calculus tilts heavily in favor of IL-17 therapy. But patients with a history of recurrent yeast infections, IBD, or significant immunosuppression should have a detailed conversation with their dermatologist before starting treatment.
Speed of Response and Why It Matters for Quality of Life
One of the less-discussed but genuinely important advantages of IL-17 inhibitors is how fast they work. Data shows that IL-17 inhibitors provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks, faster than most other biologic classes. For a patient with severe plaque psoriasis covering their arms, torso, and scalp, the difference between waiting three months for meaningful improvement and seeing dramatic clearance within six weeks is not trivial. It affects whether someone shows up for work, whether they avoid social situations, whether depression and anxiety worsen during the waiting period. Speed of response also has implications for treatment adherence. Patients who see rapid improvement are more likely to stay on therapy, refill prescriptions, and maintain the kind of consistent dosing that biologics require for sustained efficacy.
Conversely, patients who wait months for modest improvement on an older agent are more likely to become discouraged, skip doses, or abandon treatment altogether. In a disease that already carries significant psychological burden — psoriasis is associated with elevated rates of depression, anxiety, and suicidal ideation — the psychological value of rapid visible improvement should not be underestimated. There is a limitation worth noting, however. Speed of initial response does not always predict long-term durability. Some patients who respond quickly may experience a partial loss of efficacy over time, requiring dose adjustments or a switch to a different agent within the IL-17 class or to another biologic mechanism entirely. The four-year bimekizumab data is encouraging on this front, but individual variation is real, and patients should understand that the first few months of treatment, while often dramatic, are not necessarily the final word.
The Psoriasis-Brain Health Connection
For readers of a brain health and dementia care site, the relevance of psoriasis treatment may not be immediately obvious, but the connection is real and increasingly supported by research. Psoriasis is a systemic inflammatory disease, not merely a skin condition. The same inflammatory pathways that drive plaque formation — including IL-17 and related cytokines — contribute to chronic systemic inflammation that has been linked to accelerated cognitive decline, increased cardiovascular risk, and potentially elevated dementia risk.
Effective suppression of that inflammatory cascade with agents like IL-17 inhibitors may carry benefits beyond the skin, though direct evidence of neuroprotective effects remains preliminary. What is well-established is that poorly controlled psoriasis worsens depression, disrupts sleep, increases social isolation, and drives chronic stress — all of which are modifiable risk factors for cognitive decline. By restoring quality of life, enabling social engagement, and reducing the systemic inflammatory burden, effective psoriasis treatment with IL-17 inhibitors may indirectly support brain health in ways that matter for an aging population.
What Comes Next — The BE BOLD Trial and Beyond
The IL-17 inhibitor story is still being written. The most closely watched ongoing trial is BE BOLD, registered as NCT06624228, which pits bimekizumab against risankizumab, an IL-23 inhibitor. This head-to-head comparison between the two leading next-generation biologic classes will help determine whether dual IL-17 blockade or upstream IL-23 inhibition delivers superior PASI 100 outcomes and joint improvement.
The result could reshape treatment algorithms for the next decade. Meanwhile, with global psoriasis incidence projected to rise through 2050, the pressure to develop even more effective, accessible, and affordable biologic therapies will only increase. The IL-17 inhibitor class proved that complete skin clearance is a realistic goal for most patients. Whatever comes next will be measured against that standard — a standard that did not exist before January 2015.
Conclusion
IL-17 inhibitors did not just add another option to the psoriasis treatment menu. They redefined what success looks like. The shift from accepting partial improvement to expecting complete clearance — and achieving it within weeks rather than months — represents a genuine transformation in how this disease is managed.
With four FDA-approved agents offering different mechanisms, binding targets, and efficacy profiles, dermatologists now have the tools to tailor therapy to individual patients in ways that were not possible a decade ago. For patients living with moderate-to-severe psoriasis, the practical takeaway is straightforward: if your current treatment is not delivering clear or nearly clear skin, it may be time to have a conversation with your dermatologist about whether an IL-17 inhibitor is appropriate. The data supports it, the guidelines recommend it, and for most patients, the safety profile is manageable. Complete clearance is no longer an aspirational goal — it is the new standard of care.
Frequently Asked Questions
What is the difference between IL-17A inhibitors and dual IL-17A/F inhibitors?
Secukinumab and ixekizumab target only IL-17A, while bimekizumab blocks both IL-17A and IL-17F simultaneously. In head-to-head trials, this dual inhibition translated to higher rates of complete skin clearance — 61.7 percent for bimekizumab versus 48.9 percent for secukinumab at 16 weeks in the BE RADIANT trial. Brodalumab takes a third approach by blocking the IL-17 receptor itself, which also inhibits multiple IL-17 family members.
How quickly do IL-17 inhibitors work compared to older psoriasis treatments?
IL-17 inhibitors typically achieve PASI 90 responses at approximately 6 to 8 weeks, which is roughly twice as fast as most TNF inhibitors and conventional systemic therapies, which often require 12 or more weeks to reach peak effect.
Are IL-17 inhibitors safe for people with inflammatory bowel disease?
No. IL-17 inhibitors are contraindicated in patients with active Crohn’s disease or ulcerative colitis. Cases of new-onset or worsened IBD have been reported. However, analyses of 21 clinical trials found that IBD incidence rates in IL-17 inhibitor users were comparable to those in untreated psoriasis patients, so the risk may be lower than initially feared for patients without pre-existing IBD.
What is the most common side effect specific to IL-17 inhibitors?
Candidiasis, or yeast infections, is the most notable class-specific side effect, occurring at a rate of 2.2 per 100 patient-years in psoriasis clinical trials. All reported cases were mild to moderate, and no systemic candidiasis was observed. Most cases respond to standard antifungal treatment.
Can IL-17 inhibitors maintain skin clearance long-term?
Yes. Four-year data for bimekizumab showed that 64.7 percent of patients maintained complete skin clearance through 196 weeks. Five-year secukinumab data showed PASI 75 maintained at 88.5 percent and PASI 100 at 41 percent, demonstrating strong durability across the class.
Does treating psoriasis with IL-17 inhibitors have any relevance to brain health?
Psoriasis drives chronic systemic inflammation, which is increasingly linked to cardiovascular disease and potentially to accelerated cognitive decline. By suppressing this inflammatory cascade and improving quality of life, sleep, and social engagement, effective psoriasis treatment may indirectly support brain health, though direct neuroprotective evidence for IL-17 inhibitors specifically remains preliminary.
